TAG:
molecular diagnostic
Abbott Says It Will Split into Two Firms in 2012
FURTHER CHANGES ARE COMING to the in vitro diagnostics (IVD) marketplace. On October 19, Abbott Laboratories, Inc., announced that it would separate into two publicly-traded companies sometime in 2012. One business will be the medical devices and diagnostics business. It w…
Economics of Lab Testing to Be Challenged
BY ANY MEASURE, 2012 IS SHAPING UP TO BE A YEAR OF MAJOR CHANGE for healthcare and the clinical laboratory testing industry. Unfortunately, an early reading of the tea leaves indicates that the outcomes are not likely to be favorable for most clinical laboratories and anatomic pathology groups. Letâ…
Medicare Carrier Plans to Reject Molecular Claims
CEO SUMMARY: In September, Palmetto, a Medicare carrier serving California and seven other states, made public two draft local coverage determinations (LCDs) that revamp its coverage guidelines for molecular diagnostic tests (MDT) and laboratory-developed tests (LDT). All labs su…
Rosetta Genetics, Aureon Biosciences, Plus Diagnostics, Atherotech, Sequenom
ROSETTA GENOMICS TO LAY OFF 35 EMPLOYEES TO CUT EXPENSES AND SHIFT MORE FUNDING toward sales of its proprietary molecular tests, Rosetta Genomics says it will eliminate 35 jobs. The company, based in Israel, operates a clinical laboratory in Philadelphia, Pe…
How Digital Pathology Helps Pathologists Deliver Added Value
“Pathologists have the opportunity to take on a new clinical role as the integrator of all that digital pathology information, in combination with the patient’s other clinical data collected from a wide variety of sources.†—Dirk G. Soenksen, M.S., M.B.A., Founder…
Myriad Wins Federal Appeal In Important Gene Patent Suit
IN THE CLOSELY-WATCHED COURT CHALLENGE involving gene patents, Myriad Genetics, Inc., of Salt Lake City, Utah, recently won a favorable decision from the federal appeals court. However, legal experts believe that the plaintiffs are likely to ask the Supreme Court to review the case. …
Solstas Lab Partners, DNA Direct, Pathology, Inc., Slone Partners, PAML
SPECTRUM-CARILION NOW WILL BE CALLED SOLSTAS LAB PARTNERS IT IS THE NEXT STEP IN THE INTEGRATION of Spectrum Laboratory Network and Carilion Laboratories. Effective February 1, 2011, their combined businesses will use the name Solsta…
Our Top Ten Lab Stories Highlight Major Changes
CEO SUMMARY: What makes 2010 a watershed year for the laboratory testing industry is enactment of the 2,700-page Patient Protection and Affordable Care Act (PPACA). Even if parts of this bill are repealed, the remaining parts of the massive legislation will trigger major changes …
Tapping Molecular Pathology’s New Gold Mine
IN ONE SENSE, WE CAN SAY THAT THE DECADE OF 2001 THROUGH 2010 was bookended by two one-half billion dollar anatomic pathology acquisitions. Each transaction was a powerful signal to Wall Street investors. Unfortunately, most pathologists are not tuned into that signal and so continue to miss the mess…
Gauging the Prospects For Anatomic Pathology
CEO SUMMARY: More buyers are crowding into the lab testing industry and looking to acquire anatomic pathology testing companies. These buyers are willing to pay strong prices to acquire AP labs and companies which they determine to be a strategic fit. All of this acquisition acti…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.